Consistent with the survival data, SOD1-ALS patients with R116G variants showed a median disease progression rate of 0.12 ALSFRS-R points lost per month (IQR 0.07-0.20) between onset and last visit, which was more pronounced compared to patients with pathogenic D91A (0.03, IQR 0.02–0.08; n = 8; p = 0.02) and L145F variants (median 0.06, IQR 0.04–0.14; n = 6; p = 0.21), while D91A and L145F patients showed a quite similar, slow median progression rate (p = 0.35; Fig. 1b). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.